Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Temporal evolution of cellular heterogeneity during the progression to advanced, AR-negative prostate cancer [RRBS]

ABSTRACT: Temporal evolution of cellular heterogeneity during the progression to advanced, AR-negative prostate cancer [RRBS]

PROVIDER: PRJNA636399 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR11903134.fastq.gz	Fastqsanger.gz
	SRR11903135.fastq.gz	Fastqsanger.gz
	SRR11903136.fastq.gz	Fastqsanger.gz
	SRR11903137.fastq.gz	Fastqsanger.gz
	SRR11903138.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

Temporal evolution of cellular heterogeneity during the progression to advanced, AR-negative prostate cancer [RRBS]

Project description:Despite advances in the development of highly effective androgen receptor (AR)-directed therapies for the treatment of men with advanced prostate cancer, acquired resistance ultimately ensues. A significant subset of patients with resistant disease develop AR-null, androgen-indifferent tumors that lose their luminal identify and display neuroendocrine features (neuroendocrine prostate cancer (NEPC)). Utilizing a genetically engineered mouse model, we have characterized the synergy between N-Myc overexpression and RB1 loss-of-function which results in the formation of AR-negative, poorly differentiated tumors with high metastatic potential. Single-cell-based approaches revealed striking changes to the transcriptome and chromatin accessibility during the transition to NEPC. Global DNA methylation and the N-Myc cistrome are redirected following RB1 loss. Altogether, our data provide new insight into the progression to NEPC.

2021-04-07 | GSE151581 | GEO

Temporal evolution of cellular heterogeneity during the progression to advanced, AR-negative prostate cancer

Project description:Temporal evolution of cellular heterogeneity during the progression to advanced, AR-negative prostate cancer

| PRJNA635801 | ENA